Grant ID RP210062
Awarded On August 18, 2021
Title Protein Degradation of CDK9 for Treatment of Drug-Resistant Mantle Cell Lymphoma
Program Academic Research
Award Mechanism High Impact/High Risk
Institution/Organization The University of Texas Medical Branch at Galveston
Principal Investigator/Program Director Jia Zhou
Cancer Sites Lymphoma
Contracted Amount $250,000*

*Pending contract negotiation

Lay Summary

Mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell lymphoma, shows a high possibility for disease progression and relapse even after complete remission with the current frontline therapies such as ibrutinib, venetoclax and more recently CAR T therapy approved by FDA with clinical trials led by Dr. Wang (co-PI in this proposal). Once relapsed, the patients will face more aggressive disease that requires immediate alternative therapies to overcome the resistance. Developing novel therapeutic approaches to overcome drug-resistance in MCL thus represents an unmet medical need. Inspired by our recent advances in translational and preclinical studies and the initiation of ph...

Read More